Baldwin Wealth Partners LLC MA Buys 12,314 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Baldwin Wealth Partners LLC MA lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 128.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,871 shares of the company's stock after purchasing an additional 12,314 shares during the period. Baldwin Wealth Partners LLC MA's holdings in Hims & Hers Health were worth $646,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in HIMS. Vanguard Group Inc. increased its stake in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the sale, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at $5,900,796.90. This trade represents a 42.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 622,467 shares of company stock worth $25,513,488. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded down $1.71 during midday trading on Tuesday, hitting $55.15. 38,232,363 shares of the company's stock were exchanged, compared to its average volume of 20,874,016. The stock has a 50-day moving average price of $42.75 and a two-hundred day moving average price of $37.55. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The company has a market cap of $12.35 billion, a P/E ratio of 125.35 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.05 EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HIMS. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Needham & Company LLC raised their price target on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.